Pfizer drug extends life for people with rare form of lung cancer

Lorlatinib was tested in a clinical trial of hundreds of people with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).

from Business News, Finance News, Market News, Stock News, BSE, NSE, Nifty | The Hindu